Hyaluronic acid vitreous substitute. A six-year clinical evaluation.
Hyaluronic acid vitreous substitute (HYVISC) was used during 347 operations performed on 294 eyes of 286 patients. It was injected intraocularly in 266 operations (73 scleral bucklings, 175 open-sky vitrectomies, among others) on eyes with complex retinal detachments that were considered inoperable by ordinary surgical techniques. During 81 closed vitrectomies, it was applied extraocularly between the surgical contact lens and the cornea. Hyaluronic acid was found to be well tolerated by human eyes. In eyes that had been given a poor prognosis, scleral buckling with hyaluronic acid tamponade produced reattachment in 16% of the eyes; open-sky vitrectomy, scleral buckling, and hyaluronic acid salvaged 18%. It also appeared helpful in the preservation of corneal epithelial integrity and clarity during closed vitrectomy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage; D007223:Infant; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D012163:Retinal Detachment / Q000601:surgery; D012591:Scleral Buckling; D014822:Vitreous Body / Q000601:surgery
D006820:Hyaluronic Acid